An introduction to the Endpoints 100
I’m well into a new project at Endpoints that I’d like to tell you about. It’s called the Endpoints 100. (Update: List of executives is at the bottom of this article.)
For the 14 or so years that I’ve covered biotech on a daily basis, I’ve seen some dramatic shifts in biotechs’ access to capital, attitudes about regulatory conditions for new drug approvals (on both sides of the Atlantic), views on gender diversity, along with a whole new focus on drug pricing and the future of the industry. Usually, these trends and attitudes are all tracked in retrospective analyses.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters